ClinicalTrials.gg
CompletedNCT03496350Updated Feb 20, 2020

Internet-delivered Cognitive Behavioural Therapy in Arabic for Anxiety and Depression

An interventional study of Internet-delivered CBT in Anxiety and Depression, sponsored by Linkoeping University. Completed at 1 site in Sweden. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-02-20.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Linkoeping University · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 29 studies in Depression by Linkoeping University — 4 open to participants now, 7 under way, none of them phase 3. Depression · Linkoeping University.

Enrollment
21st of 27
59 · median 81
Started
2019
the only one that year
No phase
26 of 29
4 open now
Registered
14th of 29
by date

Among the 29 studies in Depression by Linkoeping University, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2019, is one of 26 with no phase, and was the 14th registered.

Depression

8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.

Browse Depression studies →

Open to participants now

4 of the 29 studies in Depression by Linkoeping University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Depression by Linkoeping University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of a culturally adapted internet-administrated cognitive behaviour therapy (ICBT) in Arabic for anxiety and depression

Read the detailed description

The study will compare the effect of the intervention against a wait-list control. The intervention tested is based on cognitive behavior therapy delivered over the internet via a secure treatment platform. Participants in the study are recruited from the general public via social media. The intervention is in Arabic.

03

Conditions studied

  • Anxiety
  • Depression

Browse trials for

04

In context

Depression Reclassified

8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.

This study's enrollment of 59 is below the median of 81 across 7,066 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Linkoeping University is the lead sponsor of 193 studies on the registry; 40 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be above 18 years of age
  • Have symptoms of anxiety and/or depression
  • Be able to read and write in Arabic
  • Have access to computer or smartphone

Exclusion criteria

Exclusion Criteria:

  • Suicidal ideation
  • Alcohol addiction
  • Other major primary psychiatric disorder
  • Ongoing psychological treatment
  • Recent (during last 4 weeks) change in psychiatric medication
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Internet CBT

    Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.

    Behavioral: Internet-delivered CBT

  • No intervention
    Wait-list

    Wait-list control

Interventions

  • BehavioralInternet-delivered CBT

    Culturally adapted transdiagnostic internet-delivered CBT in Arabic

07

What researchers measure

Primary outcomes

  1. Change in Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a nine-item self-report questionnaire that measures symptoms of depression. It is scored from 0-27 with a higher score reflecting more severe symptoms.

    Time frame: pre-treatment ,week 3, week 6, week 8 and 12 months post-treatment

  2. Change in Generalised Anxiety Disorder-7-item scale, (GAD-7)

    The GAD-7 is a seven-item self-report questionnaire that measures symptoms of anxiety. It is scored from 0-21 with a higher score reflecting more severe symptoms.

    Time frame: pre-treatment ,week 3, week 6, week 8 and 12 months post-treatment

Secondary outcomes

  1. Alcohol Use Disorder Identification Test (AUDIT)

    Measures alcohol consumption, drinking behaviors, and alcohol-related problems. It is scored from 0-40 with higher scores reflecting more alcohol consumption, drinking behaviors, and alcohol-related problems.

    Time frame: pre-treatment, week 8

  2. Insomnia Severity Index (ISI)

    Self-reported symptoms of insomnia. It is scored from 0-28 with higher scores reflecting more symptoms of insomnia.

    Time frame: pre-treatment, week 8

  3. Impact of Events Scale - Revised (IES-R)

    Self-reported symptoms of post-traumatic stress. It is scored from 0-88 where higher scores reflect more symptoms.

    Time frame: pre-treatment, week 8

  4. Perceived Stress Scale (PSS)

    Self-reported stress-related symptoms. It is scored from 0-56 with higher scores reflecting more symtoms of perceived stress.

    Time frame: pre-treatment, week 8

  5. "Brunnsviken Brief Quality of Life Scale" (BBQ)

    Self-reported quality of life. The scale is scored from 0-96 with a higher score reflecting higher self-reported quality of life.

    Time frame: pre-treatment, week 8

08

Study locations

1 site
  • Linköping University
    Linköping, 581 83, Sweden
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Dec 2019, 10 months.

Of 3,471 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 10 months is below that.

Counting every sponsor, half of 3,569 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 12, 2018
StartActual
Jan 7, 2019
Primary completionActual
Dec 1, 2019
CompletionActual
Dec 1, 2019
Last update
Feb 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03496350
Responsible party
Gerhard Andersson (Professor, Linkoeping University) — Principal investigator
First posted
Apr 12, 2018
Start date
Jan 7, 2019
Primary completion
Dec 1, 2019
Completion
Dec 1, 2019
Last update
Feb 20, 2020

Study contacts

Gerhard Andersson, PhD
principal investigator · Linkoeping University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion